GLP-1 side effects and tips: fact-checking the TikTok claims

What did @charitykface actually say?

The creator is openly dosing her GLP-1 medication every five days instead of the standard seven, and she says plainly: "there isn't any rhyme or reason why I still take it every five days." Her motivation is fear of regaining weight, and she has access to enough medication to sustain this schedule because she sources it from what she describes as a Chinese supplier. She frames the outcome as stable: "I'm not losing and I'm not gaining. I'm good."

So this is not a claim about accelerating weight loss. It is a claim that a self-modified, shorter dosing interval is a reasonable maintenance strategy. That framing matters for the fact-check, because the question is not whether she feels fine, it is whether what she is doing is pharmacologically sound or potentially harmful.

Does the science back this up?

Not really. The every-five-days schedule has no clinical trial support, and the pharmacokinetics of semaglutide actually make it unnecessary. Semaglutide has a half-life of approximately one week, which is precisely why it was designed as a once-weekly injection. That long half-life means plasma concentrations stay relatively stable between doses when you dose weekly.

When you shorten the interval to five days without reducing the dose, you are increasing the frequency of peak plasma exposure. There is no published data showing this improves outcomes, and there is plausible reason to think it could increase side effect burden. Davies et al. (2021, The Lancet) and the SUSTAIN trial series established the weekly dosing schedule as optimized for both efficacy and tolerability. No peer-reviewed study has tested a five-day interval for semaglutide as a weight maintenance strategy. The creator is essentially running an n-of-1 experiment with no control.

What did they get wrong (or right)?

She got one thing right: weight regain after stopping or reducing GLP-1 therapy is a real and well-documented concern. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found that participants regained roughly two-thirds of lost weight within one year of stopping semaglutide. Her fear is grounded in real pharmacology.

What she got wrong, or at least what deserves scrutiny, is the leap from "I'm scared to stop" to "I'll dose every five days indefinitely with no medical guidance." That is not a clinical strategy. It is an anxiety-driven workaround. The phrase "there isn't any rhyme or reason" is actually more honest than most influencer content, but honesty about doing something unsupported is not the same as that thing being safe. Sourcing medication from an unverified international supplier adds another layer of risk: no oversight of compounding quality, concentration accuracy, or sterility.

What should you actually know?

If you are on a GLP-1 medication and worried about weight regain, that is a legitimate clinical conversation to have with a prescriber. It is not a reason to self-modify your dosing interval. The FDA-approved maintenance approach is continued weekly dosing at the lowest effective dose, not accelerated dosing on a self-determined schedule.

Sourcing GLP-1 medications from unverified international suppliers, which is what "Chinese supplier" almost certainly refers to here, carries real risks. You cannot verify the peptide concentration, sterility, or excipient composition of these products. Compounded semaglutide from a 503A or 503B facility in the U.S. operates under very different regulatory conditions than a product shipped internationally with no supply chain transparency.

• Semaglutide's half-life is approximately 7 days. Weekly dosing is not arbitrary; it is built around that pharmacokinetic profile.
• Five-day dosing is not supported by any published clinical trial.
• Weight regain after GLP-1 discontinuation is real, but the answer is supervised continuation, not unsupervised interval modification.
• If you are sourcing from an unverified supplier, you do not know what you are injecting.